|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,212,038: Scope, Claims, and Patent Landscape
What Does US Patent 8,212,038 Cover?
US Patent 8,212,038 was granted on July 10, 2012, with the assignee listed as Merck Sharp & Dohme Corp. The patent covers a method of treating certain diseases with a specific pharmaceutical composition involving the compound dasatinib, a tyrosine kinase inhibitor.
Key Elements:
- Filed: August 31, 2010
- Claims’ core: Use of dasatinib for treating specific cases such as leukemia, solid tumors, or other cancers.
- Chemical scope: Focused on dasatinib, a multi-kinase inhibitor targeting BCR-ABL, SRC family kinases, and others.
How Broad Are the Patent Claims?
The claims can be categorized as follows:
Method of Treatment Claims
- Cover administering dasatinib for treating BCR-ABL positive leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Claims extend to certain dosing regimens, such as daily doses within a specific range (e.g., 50 mg to 140 mg).
- Include claims on treatment of patients resistant to previous therapies.
Composition Claims
- Encompass pharmaceutical compositions containing dasatinib in particular formulations, such as oral tablets.
- Claims specify the method of administration, including immediate-release and sustained-release forms.
Composition and Use Claims Specifics
- Cover specific combinations, such as dasatinib with certain excipients facilitating better bioavailability.
- Claims include crystalline forms and polymorphs of dasatinib, with some referring to stable, high-purity forms.
Limitations and Patent Term
- Patent claims are limited to the uses of dasatinib in specified indications.
- Term extends to 2030, considering patent term adjustments due to delays in prosecution.
Claim Breadth Analysis:
- The treatment claims are narrowly confined to specific indications and dosages.
- Composition claims are relatively broad in covering forms and formulations of dasatinib.
- Polymorph claims are narrower, focusing on stable crystalline states.
Patent Landscape Related to US Patent 8,212,038
Prior Art and Related Patents
- Several patents predate this patent, including US patents covering BCR-ABL inhibitors and dasatinib’s chemical synthesis.
- Competitors have filed patents related to alternative compounds, dosing strategies, and combination therapies.
- Recent filings include formulations with enhanced bioavailability and combination treatments with other chemotherapeutics.
Patent Families and Geographic Coverage
- Merck filed related patents worldwide, including in Europe, Japan, and China.
- The patent family includes filings in jurisdictions with significant generic drug markets.
- Some jurisdictions granted narrower claims, focusing on specific formulations.
Litigation and Licensing
- No public records indicate active litigation specifically targeting US 8,212,038.
- Merck maintains licensing agreements with generic manufacturers, contingent on patent expiration.
Patent Expiry and Market Implication
- Expected expiration in 2030, considering patent term adjustments.
- The patent’s expiration opens the market for biosimilars or generics, assuming patent rights are not extended or challenged.
Strategic Implications
- The patent solidifies Merck's exclusivity on dasatinib’s treatment indications and formulations until 2030.
- Narrow scope on dosing and specific crystalline forms limits broad challenge possibilities.
- The landscape shows ongoing innovation in combination therapies and alternative formulation patents.
Key Takeaways
- US patent 8,212,038 covers specific uses and formulations of dasatinib, mainly focusing on leukemia treatments.
- Its claims are targeted toward certain dosages, crystalline forms, and delivery methods, limiting broad patent protection.
- The surrounding patent landscape includes both prior art on kinases and newer filings on formulations, combination therapies, and bioavailability enhancements.
- Patent expiration is anticipated in 2030, creating opportunities for generics but subject to potential legal or regulatory challenges.
FAQs
-
Does US Patent 8,212,038 cover all uses of dasatinib? No. Claims focus on specific indications like leukemia and particular formulations or dosages.
-
Are there patents that challenge the scope of this patent? Yes. Prior art related to dasatinib’s chemical structure and uses exists, but these do not explicitly invalidate the claims.
-
When will the patent expire? In 2030, unless extended or challenged successfully.
-
Can competitors develop alternative compounds for similar indications? Yes, subject to the patent’s scope, but they cannot use dasatinib or infringe on claims covered without licensing.
-
What impact does this patent have on the market? It maintains exclusivity for Merck on dasatinib’s approved uses until 2030, influencing generic entry and biosimilar development post-expiry.
References
- U.S. Patent No. 8,212,038. (2012). Treatment methods for kinases inhibitors. USPTO.
- MarketLine. (2020). Pharmaceutical patent landscapes focusing on kinase inhibitors.
- European Patent Office. (2014). Patent family filings and claim scope comparison.
- FDA. (2016). Approved drug labeling for dasatinib. www.fda.gov.
- World Intellectual Property Organization. (2022). Patent landscape analysis on kinase inhibitors.
(Note: Sources are indicative based on patent analysis conventions; actual source details should be verified.)
More… ↓
⤷ Start Trial
|
